Katerina Kubackova1, Bohuslav Melichar2, Zbynek Bortlicek3, Tomas Pavlik3, Alexandr Poprach4, Marek Svoboda4, Radek Lakomy4, Rostislav Vyzula4, Igor Kiss4, Ladislav Dusek3, Jana Prausova1, Tomas Buchler5. 1. Department of Oncology, University Hospital in Motol, Charles University, Prague, Czech Republic. 2. Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic. 3. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 4. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 5. Department of Oncology and First Faculty of Medicine, Thomayer Hospital and Charles University, Prague, Czech Republic. tomas.buchler@ftn.cz.
Abstract
BACKGROUND: The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC). METHODS: Data from patients who met prognostic model criteria for recording of baseline parameters and outcomes in the Czech Patient Registry RENal Information System (RENIS) were included in the retrospective analysis (n = 495). Performance of the modified Memorial Sloan Kettering Cancer Center (MSKCC) model and International Database Consortium (IDC) model was compared. PFS and OS were estimated using the Kaplan-Meier method. The statistical significance of differences in Kaplan-Meier estimates was assessed using the log-rank test. RESULTS: Median OS for prognostic groups according to MSKCC and IDC criteria, respectively, was 39.5 months (95 % confidence interval [CI]: 23.9-55.2) versus 44.3 months (95 % CI: 31.6-56.9) for favourable-risk patients (no adverse factors), 28.5 months (95 % CI: 20.1-36.8) versus 24.8 months (95 % CI: 19.8-29.8) for intermediate-risk patients (1-2 adverse factors), and 10.6 months (95 % CI: 6.3-14.8) versus 9.3 months (95 % CI: 5.1-13.5) for poor-risk patients (≥3 adverse factors). The majority of MSKCC poor-risk patients (54.1 %, n = 72) were reclassified as intermediate-risk using IDC criteria, and 20.2 % (n = 61) of MSKCC intermediate-risk patients were reclassified to the IDC favourable-risk group. CONCLUSIONS: Both prognostic models were validated in the present cohort. Use of the IDC model resulted in an upward shift in prognostic assessment compared to the MSKCC model.
BACKGROUND: The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC). METHODS: Data from patients who met prognostic model criteria for recording of baseline parameters and outcomes in the Czech Patient Registry RENal Information System (RENIS) were included in the retrospective analysis (n = 495). Performance of the modified Memorial Sloan Kettering Cancer Center (MSKCC) model and International Database Consortium (IDC) model was compared. PFS and OS were estimated using the Kaplan-Meier method. The statistical significance of differences in Kaplan-Meier estimates was assessed using the log-rank test. RESULTS: Median OS for prognostic groups according to MSKCC and IDC criteria, respectively, was 39.5 months (95 % confidence interval [CI]: 23.9-55.2) versus 44.3 months (95 % CI: 31.6-56.9) for favourable-risk patients (no adverse factors), 28.5 months (95 % CI: 20.1-36.8) versus 24.8 months (95 % CI: 19.8-29.8) for intermediate-risk patients (1-2 adverse factors), and 10.6 months (95 % CI: 6.3-14.8) versus 9.3 months (95 % CI: 5.1-13.5) for poor-risk patients (≥3 adverse factors). The majority of MSKCC poor-risk patients (54.1 %, n = 72) were reclassified as intermediate-risk using IDC criteria, and 20.2 % (n = 61) of MSKCC intermediate-risk patients were reclassified to the IDC favourable-risk group. CONCLUSIONS: Both prognostic models were validated in the present cohort. Use of the IDC model resulted in an upward shift in prognostic assessment compared to the MSKCC model.
Authors: Tomáš Pavlík; Ondřej Májek; Tomáš Büchler; Rostislav Vyzula; Jiří Petera; Miroslav Ryska; Aleš Ryška; David Cibula; Marko Babjuk; Jitka Abrahámová; Jiří Vorlíček; Jan Mužík; Ladislav Dušek Journal: Cancer Epidemiol Date: 2013-12-07 Impact factor: 2.984
Authors: Tarek M Mekhail; Rony M Abou-Jawde; Gabriel Boumerhi; Sareena Malhi; Laura Wood; Paul Elson; Ronald Bukowski Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Alexandr Poprach; Zbyněk Bortlíček; Tomáš Büchler; Bohuslav Melichar; Radek Lakomý; Rostislav Vyzula; Petr Brabec; Marek Svoboda; Ladislav Dušek; Jakub Gregor Journal: Med Oncol Date: 2012-06-30 Impact factor: 3.064
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Pawel Wiechno; Jakub Kucharz; Malgorzata Sadowska; Wojciech Michalski; Bozena Sikora-Kupis; Joanna Jonska-Gmyrek; Grazyna Poniatowska; Karol Nietupski; Krzysztof Ossolinski; Tomasz Demkow Journal: Med Oncol Date: 2018-10-27 Impact factor: 3.064